The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While both classes demonstrate remarkable efficacy in achieving glycemic control and facilitating substantial weight reduction, key … Read More

The burgeoning landscape of innovative treatments for weight management has seen the rise of both glp-3 retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeu… Read More